Catabasis Pharmaceuticals Presents Preclinical Data Showing Potential for Bone Preservation with Edasalonexent in Duchenne Muscular Dystrophy

Stock Information for null

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About null

Catabasis Pharmaceuticals Announces New Company Name, Astria Therapeutics, Highlighting New Company Focus
Catabasis Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides a Corporate Update
Catabasis Pharmaceuticals to Present at 2021 Wedbush PacGrow Healthcare Conference
Catabasis Pharmaceuticals To Present At Ladenburg Thalmann 2021 Healthcare Conference
Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences
 Catabasis Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides a Corporate Update
Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update
Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences   

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.